SarcoMed USA was formed in 2017 to investigate if a novel DNase 1 compound (SM001) could influence the chronic pulmonary inflammation seen in Pulmonary Sarcoidosis patients.
Sarcoidosis is a systemic granulomatous disease characterized by a T-helper-1 response with accumulation of CD4+ lymphocytes and activated macrophages in the lungs and affected organs, resulting in characteristic granuloma formation. The lungs are invol...
SarcoMed USA was formed in 2017 to investigate if a novel DNase 1 compound (SM001) could influence the chronic pulmonary inflammation seen in Pulmonary Sarcoidosis patients.
Sarcoidosis is a systemic granulomatous disease characterized by a T-helper-1 response with accumulation of CD4+ lymphocytes and activated macrophages in the lungs and affected organs, resulting in characteristic granuloma formation. The lungs are involved in more than 90% of patients with sarcoidosis, thus abnormal pulmonary function is characteristic for many patients. Sarcoidosis affects approximately 200,000 people in the United States.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.